J&J’s Ophthalmic Surgical Division Reports $319 Million in Revenues for Q4-2017

February 2, 2018: By Jon Swedien

Johnson & Johnson’s ophthalmic surgical division posted $319 million in revenues in Q4-2017, J&J reported Jan. 23.

The division generated $1 billion in revenues for the full year, the company reported.

J&J completed its acquisition of the surgical division (formerly Abbott Medical Optics) in February 2017. The AMO acquisition contributed 4.5 percent to worldwide operational sales growth, J&J said.

J&J Vision—which includes the surgical division and the company’s contact lens division—posted $1.1 billion in sales in the fourth quarter of 2017. It generated $4.1 billion in revenues for the full year, the company said.

The entire company’s sales for Q4-2017 were $20.2 billion, an increase of 11.5 percent compared with Q4-2016. The company’s sales for the full year were $76.5 billion, up 6.3 percent compared with 2016, J&J reported.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility